November 17, 2016 - By Nellie Frank · 0 Comments
ARGOS THERAPEUTICS INC (NASDAQ:ARGS) institutional sentiment increased to 4.83 in 2016 Q2. Its up 3.75, from 1.08 in 2016Q1. The ratio has increased, as 29 investment managers increased or opened new stock positions, while 6 sold and reduced their holdings in ARGOS THERAPEUTICS INC. The investment managers in our partner’s database reported: 8.64 million shares, up from 3.38 million shares in 2016Q1. Also, the number of investment managers holding ARGOS THERAPEUTICS INC in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 5 Increased: 10 New Position: 19.
Argos Therapeutics, Inc. is an immuno-oncology company. The company has a market cap of $210.27 million. The Firm is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. It currently has negative earnings. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
The stock decreased 2.00% or $0.1 during the last trading session, hitting $4.9. Argos Therapeutics Inc (NASDAQ:ARGS) has declined 55.33% since April 15, 2016 and is downtrending. It has underperformed by 59.96% the S&P500.
Analysts await Argos Therapeutics Inc (NASDAQ:ARGS) to report earnings on November, 21. They expect $-0.29 EPS, up 70.10% or $0.68 from last year’s $-0.97 per share. After $-0.48 actual EPS reported by Argos Therapeutics Inc for the previous quarter, Wall Street now forecasts -39.58% EPS growth.
According to Zacks Investment Research, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States.”
Wall Street Associates holds 0.45% of its portfolio in Argos Therapeutics Inc for 185,097 shares. Wasatch Advisors Inc owns 2.39 million shares or 0.22% of their US portfolio. Moreover, Altrinsic Global Advisors Llc has 0.03% invested in the company for 172,505 shares. The Texas-based Bridgeway Capital Management Inc has invested 0.01% in the stock. Oxford Asset Management, a United Kingdom-based fund reported 57,647 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 8 buys, and 0 sales for $1.78 million net activity.
Ratings analysis reveals 100% of Argos Therapeutics’s analysts are positive. Out of 4 Wall Street analysts rating Argos Therapeutics, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $12 while the high is $18. The stock’s average target of $14.25 is 190.82% above today’s ($4.9) share price. ARGS was included in 5 notes of analysts from November 16, 2015. The firm has “Outperform” rating by FBR Capital given on Thursday, August 11. Needham maintained the shares of ARGS in a report on Tuesday, November 17 with “Buy” rating. As per Monday, November 16, the company rating was maintained by FBR Capital. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. Roth Capital maintained Argos Therapeutics Inc (NASDAQ:ARGS) on Tuesday, April 19 with “Buy” rating.
Argos Therapeutics, Inc. (Argos), incorporated on May 8, 1997, is an immuno-oncology company. The Firm is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s product candidates include AGS-003 and AGS-004.
More notable recent Argos Therapeutics Inc (NASDAQ:ARGS) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on March 04, 2012, also Reuters.com with their article: “BRIEF-Russia’s Pharmstandard invests in Argos Therapeutics Inc” published on March 24, 2016, Globenewswire.com published: “Argos Therapeutics Announces Pricing of $50 Million Public Offering of Common …” on July 28, 2016. More interesting news about Argos Therapeutics Inc (NASDAQ:ARGS) were released by: Quotes.Wsj.com and their article: “News Argos Therapeutics Inc.ARGS” published on February 25, 2012 as well as Bizjournals.com‘s news article titled: “Durham’s Argos expands cancer-fighting scope with new trial” with publication date: March 24, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank